MRI of Myocardial Infarction (MRIMI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03531151 |
Recruitment Status :
Recruiting
First Posted : May 21, 2018
Last Update Posted : April 17, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Myocardial Infarction Myocardial Ischemia Myocardial Injury Myocardial Fibrosis Myocardial Reperfusion Injury Myocardial Edema Myocardial Necrosis Heart Failure Ischemic Heart Disease Ischemic Cardiomyopathy Hemorrhage |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 70 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 5 Years |
Official Title: | Magnetic Resonance Imaging of Myocardial Infarction |
Actual Study Start Date : | April 1, 2018 |
Estimated Primary Completion Date : | March 31, 2023 |
Estimated Study Completion Date : | March 31, 2023 |

- ejection fraction [ Time Frame: <36 hours to >6 months ]
- relaxation times [ Time Frame: <36 hours to >6 months ]
- extracellular volume fraction [ Time Frame: <36 hours to >6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Between the ages of 18 and 80
- Patients must be able to read and understand English
- Participants must sign the informed consent form
- Elevated and delayed peak creatine kinase-MB and troponin I (cTnI) and troponin T (cTnT) in blood serum,
- ST elevation detected on ECG
Exclusion Criteria:
- contraindications to cardiac MRI, including claustrophobia
- advanced renal disease (estimated glomerular filtration rate 30 mL/min) or hypersensitivity to gadolinium
- presence of a cardiac pacemaker or implanted cardiac cardioverter defibrillator
- pregnancy
- personal or family history of hypertrophic cardiomyopathy
- inability to provide informed consent
- history of seizure disorder

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03531151
United States, Pennsylvania | |
University of Pennsylvania | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Contact: Walter R Witschey, PhD 215-662-2310 witschey@pennmedicine.upenn.edu |
Additional Information:
Responsible Party: | University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT03531151 History of Changes |
Other Study ID Numbers: |
827697 |
First Posted: | May 21, 2018 Key Record Dates |
Last Update Posted: | April 17, 2019 |
Last Verified: | April 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Heart Diseases Myocardial Infarction Coronary Artery Disease Coronary Disease Cardiomyopathies Myocardial Ischemia Reperfusion Injury Myocardial Reperfusion Injury Ischemia Infarction |
Hemorrhage Necrosis Wounds and Injuries Cardiovascular Diseases Pathologic Processes Vascular Diseases Arteriosclerosis Arterial Occlusive Diseases Postoperative Complications |